Latest News

Your daily dose of the clinical news you may have missed.

Blood-based monitoring could enable earlier intervention as approximately 20% of initially negative participants transitioned to positive biomarker status.

Topical roflumilast 0.3% improved IGA, PASI, itch, and symptom scores in plaque psoriasis with a safety profile comparable to vehicle.

KT-621 achieved deep STAT6 degradation and strong 4-week EASI and itch reductions, offering a potential new oral option for moderate–severe AD and other Th2 inflammation-driven disease.

The study supports the feasibility of structured operational strategies to narrow dangerous gaps in guideline-recommended inpatient OSA testing, authors wrote.

Chari A. Cohen, DrPH, MPH, underscored the importance of trust, open dialogue, and evidence-based information.

Highlights include widespread lack of structured menopause education in primary care residency programs, sleep benefits of elinzanetant, and more.

Amid controversy, ACIP voted today to end the universal hepatitis B birth dose for infants of HBsAg-negative mothers, shifting to clinician-guided individual decision-making.